Suzetrigine received approval from the FDA on January 30, 2025, as a small-molecule pharmaceutical for the treatment of moderate to severe acute pain in adults.
The combination drug Meloxicam and Rizatriptan, received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025, for the treatment of migraine.
Limertinib is a newly developed small-molecule chemical drug, specifically designed as an inhibitor targeting the epidermal growth factor receptor (EGFR) T790M mutation.
Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.
Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.
In this article, we present a comprehensive overview of drugs that received their first global approvals in January 2025, along with an analysis of these therapies.